Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions, Inc. (NYSE: EBS) is a global life sciences company dedicated to protecting and enhancing life. With a mission to secure public health, Emergent develops, manufactures, and distributes a broad portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company is committed to safeguarding lives and aims to protect and enhance 50 million lives with its products by 2025.
Headquartered in Gaithersburg, Maryland, Emergent operates through three primary segments: Commercial, Products, and Services. The Commercial segment, which generates the majority of the company's revenue, includes key products such as NARCAN® Nasal Spray—a life-saving medication for opioid overdoses. NARCAN® has become widely accessible in pharmacies, grocery stores, and online retailers, significantly increasing public availability since its over-the-counter approval by the FDA in March 2023.
Emergent is also known for its role in developing and manufacturing vaccines and therapeutics, particularly for governments and healthcare providers. The company's Baltimore Bayview manufacturing facility recently received a “No Action Indicated” status from the FDA, confirming its compliance with good manufacturing practices. This recognition underscores Emergent's dedication to quality and compliance in its manufacturing processes.
Financially, Emergent is focused on stabilizing its operations and strengthening its balance sheet. The recent restructuring plan aims to streamline operations, close certain manufacturing facilities, and reduce workforce by 300 employees, resulting in annualized savings of approximately $80 million. Despite these changes, Emergent remains dedicated to its core business areas and continues to offer integrated contract development and manufacturing services to pharmaceutical and biotechnology customers.
Key recent developments include the extension of NARCAN® Nasal Spray's shelf life from 36 to 48 months and its widespread distribution across the U.S. and Canada. Emergent is also actively working with partners like the National Safety Council to educate businesses and the public about opioid overdose prevention and response.
Emergent is committed to its long-term vision of protecting and enhancing 1 billion lives by 2030. The company continues to innovate and expand its product offerings while maintaining a strong focus on public health and safety.
Emergent BioSolutions Inc. (NYSE: EBS) announced a conference call on April 28, 2022, at 5:00 PM ET to discuss its Q1 2022 financial results, recent business developments, and revenue guidance for Q2 2022 and the full year 2022.
Investors can participate via telephone or webcast. The toll-free dial-in number is (855) 766-6521, with a conference ID of 3691528. A replay will be available on the company’s website following the call.
Emergent BioSolutions (NYSE: EBS) announced significant governance changes on March 23, 2022. Effective April 1, 2022, Zsolt Harsanyi, Ph.D., will serve as the new chairman of the board, following the elimination of the executive chairman role. Keith Katkin has been appointed as an independent director. Additionally, new chairs for the audit, strategic operations, and scientific review committees have been designated. These changes reflect the company's commitment to improved corporate governance and strategic execution, promoting shareholder value and enhancing operational efficacy.
Emergent BioSolutions (NYSE: EBS) has announced its participation in several upcoming investor conferences. Notable events include the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, with a fireside chat at 1:30 PM ET, and the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:00 PM ET. Additionally, Emergent will attend the Goldman Sachs 7th Annual Leveraged Finance and Credit Conference from May 11 to 13, 2022, with further details to be provided on their website. Webcasts will be available for live viewing and replay.
Emergent BioSolutions (NYSE: EBS) has initiated a Phase 1 study administering stabilized isoamyl nitrite (SIAN) for acute cyanide poisoning treatment. The first participant was dosed on March 11, 2022. This study, funded by BARDA, aims to evaluate SIAN's safety, tolerability, and pharmacokinetics. Targeting 70 healthy participants aged 18-45, SIAN will be developed as an intranasal spray for first responders and civilians. The R&D aligns with Emergent's focus on critical public health threats.
Emergent BioSolutions (EBS) reported Q4 2021 revenues of $723.2 million, a 24% increase from Q4 2020. For FY 2021, total revenues reached $1.79 billion, up 15% year-over-year, while Adjusted EBITDA was $517.6 million (down 18%). The company revised its 2022 guidance downwards, expecting revenues of $1.3 to $1.4 billion due to operational adjustments. Key highlights included a 56% revenue increase in nasal naloxone products and a new supply agreement with Sandoz for an authorized generic of NARCAN. However, net income declined 24% for the year.
Emergent BioSolutions (NYSE: EBS) will hold a conference call on February 24, 2022, at 5:00 PM ET to discuss its fourth-quarter 2021 financial results and business developments. The call will provide insights into the financial outlook for 2022, and revenue guidance for Q1 2022. Interested participants can join via telephone or webcast. Further details regarding the conference call are available on the company's website.
Fuad El-Hibri, founder and executive chairman of Emergent BioSolutions, announced his retirement effective April 1, 2022, after over 20 years of leadership. Under his guidance, the company grew significantly, launching products that address public health threats, including vaccines for anthrax and COVID-19. El-Hibri expressed gratitude to his team for their support and confidence in the company's ongoing strategic goals for 2024. Emergent generated approximately $1.6 billion in revenue in 2020 and will soon announce a new Chair of the Board to succeed El-Hibri.
Emergent BioSolutions reported preliminary 2021 revenues of $1.78 billion, a 14% increase year-over-year, but anticipates a decline in adjusted EBITDA to $512.5 million, down 19%. For 2022, the company projects revenues of $1.45 billion and an adjusted EBITDA margin of 21.5%. The guidance reflects a normalization in CDMO services and the impact of a generic market for NARCAN® Nasal Spray. Additionally, 2022 revenue estimates for key products include $280-$300 million from Anthrax vaccines and $240-$310 million from Nasal Naloxone products.
Emergent BioSolutions (NYSE: EBS) announced participation in three major investor conferences in Q1 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 10-13, with a presentation on January 10 at 8:15 am PST. Following this, the J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference will occur from February 28 to March 2, with a presentation on February 28 at 2:00 pm EST. Lastly, the Cowen & Co. 42nd Annual Health Care Conference will take place March 7-9, with the presentation details to be updated. Webcasts will be accessible live and for replay on the company’s website.
Emergent BioSolutions Inc. (NYSE: EBS) has announced that the first participant has been dosed in its phase 1 study, EBS-UFV-001, which is assessing the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine. The study aims to evaluate the vaccine's effectiveness against influenza A viruses and is taking place in Australia with 60 healthy adults involved. The company emphasizes its commitment to innovative R&D and public health solutions, focusing on a vaccine that could provide broad protection against varying influenza strains.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
What is Emergent BioSolutions' core mission?
What are the main segments of Emergent BioSolutions?
What is NARCAN® Nasal Spray?
What recent compliance certification did Emergent receive?
What are Emergent's recent restructuring plans?
How is Emergent enhancing the availability of NARCAN® Nasal Spray?
What financial goals does Emergent have?
What is Emergent's vision for the future?
What services does Emergent offer to pharmaceutical and biotechnology customers?
How can stakeholders participate in Emergent's conference calls?
